CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types
- Status
- TERMINATED
- Phase
- PHASE1
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
- Status
- COMPLETED
- Phase
- PHASE1
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Intratumoral Microdosing of Motolimod in HNSCC
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2